{"commentary":{"count":234,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":146,"youtube":42,"podcast":38,"x_video":8},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06625320\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"RASolute 302","nct_id":"NCT06625320","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rasolute-302-nct06625320. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"RASolute 302","arms":[{"description":"Study drug","label":"RMC-6236","type":"EXPERIMENTAL"},{"description":"Patients randomized to Investigator's choice of standard of care chemotherapy will receive one of the following four treatments:\n\n* Gemcitabine and nab-paclitaxel (GnP)\n* Oxaliplatin, leucovorin, irinotecan, and 5-FU (Modified FOLFIRINOX: mFOLFIRINOX)\n* Liposomal irinotecan (Nal-IRI + 5-FU/LV)\n* Oxaliplatin, leucovorin and 5-FU IV (FOLFOX)","label":"Investigator's choice of standard of care therapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Pancreatic Cancer","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma"],"enrollment":{"count":500,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"RMC-6236","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"nab-paclitaxel","type":"DRUG"},{"name":"Irinotecan","type":"DRUG"},{"name":"Liposomal irinotecan","type":"DRUG"},{"name":"5-fluorouracil","type":"DRUG"},{"name":"leucovorin","type":"DRUG"},{"name":"Oxaliplatin","type":"DRUG"}],"last_update":"2026-06-02","lead_sponsor":"Revolution Medicines, Inc.","official_title":"RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS) in the RAS G12-mutant population","timeFrame":"Up to approximately 3 years"},{"measure":"Overall survival (OS) in the RAS G12-mutant population","timeFrame":"Up to approximately 3 years"}],"references":[{"citation":"O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM; RASolute 302 Trial Investigators. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026 Jul 23;395(4):325-337. doi: 10.1056/NEJMoa2605555. Epub 2026 May 31.","pmid":"42223072","type":"DERIVED"}],"start_date":{"date":"2024-10-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","url":"https://clinicaltrials.gov/study/NCT06625320"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rasolute-302-nct06625320"}